Deubiquitylating enzymes and disease

Shweta Singhal, Matthew C. Taylor, Rohan T. Baker

    Research output: Contribution to journalReview articlepeer-review

    73 Citations (Scopus)


    Deubiquitylating enzymes (DUBs) can hydrolyze a peptide, amide, ester or thiolester bond at the C-terminus of UBIQ (ubiquitin), including the post-translationally formed branched peptide bonds in mono- or multi-ubiquitylated conjugates. DUBs thus have the potential to regulate any UBIQ-mediated cellular process, the two best characterized being proteolysis and protein trafficking. Mammals contain some 80-90 DUBs in five different subfamilies, only a handful of which have been characterized with respect to the proteins that they interact with and deubiquitylate. Several other DUBs have been implicated in various disease processes in which they are changed by mutation, have altered expression levels, and/or form part of regulatory complexes. Specific examples of DUB involvement in various diseases are presented. While no specific drugs targeting DUBs have yet been described, sufficient functional and structural information has accumulated in some cases to allow their rapid development. Publication history. Republished from Current BioData's Targeted Proteins database (TPdb;

    Original languageEnglish
    Article numberS3
    JournalBMC Biochemistry
    Issue numberSUPPL. 1
    Publication statusPublished - 2008


    Dive into the research topics of 'Deubiquitylating enzymes and disease'. Together they form a unique fingerprint.

    Cite this